Clin2
NCT07485595Possibly a fitNot yet recruiting

JS1-1-01 tablet for moderate to severe depression

Depression

Part of Mental health clinical trials.

This trial tests a new tablet, JS1-1-01, for people with moderate to severe depression. It aims to see if the tablet is effective and safe for treating depression symptoms.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2/Phase 3
Enrollment
180 people
Ages
18 years to 65 years
Study type
Interventional

Who can take part

  • You are between 18 and 65 years old.
  • You have been diagnosed with depression for at least 3 months (if this is your first episode).
  • Your depression is moderate to severe based on a standard rating scale.
  • You are not currently taking other antidepressants or have been off them for at least 2 weeks.
  • You have not had severe side effects from other medications or are allergic to pepper plants.
  • You have not had certain therapies (like electroshock or magnetic stimulation) in the past 3 months.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06820723Recruiting· Phase 2
Testing a single dose of CYB003 for depression and anxiety

This trial tests a single dose of an investigational drug (CYB003) in people with depression and anxiety who haven't gotten enough help from their current antidepressant. You would take a psilocybin-like medication and be monitored for how it affects your mood and anxiety.

Columbus, Ohio
NCT06793397Recruiting· Phase 3
Study of an experimental psychedelic-like drug for depression (CYB003)

This study tests an investigational medication (CYB003) for people with major depression whose current antidepressant isn't working well enough. It looks at whether this treatment can help improve depression symptoms.

Birmingham, Alabama
NCT05641623Recruiting· Phase 2
Study drug for depression that didn’t improve on common antidepressants

This Phase 2 trial tests OSU6162 added to an SSRI or SNRI in people whose major depression did not improve enough after trying specific antidepressants for at least 6 weeks. It may help reduce depression symptoms when standard treatments haven’t worked well.

Lund, Skåne County
NCT06512194Recruiting· Phase 2
Psilocybin for depression study

This trial tests whether psilocybin can help people with major depression who are currently having a depressive episode. It aims to understand how the treatment works and if it is safe and effective.

Edwards, Colorado
NCT06828887Recruiting· Phase 2
Testing LV232 capsules for major depression

This trial tests a new medicine called LV232 for people with moderate to severe depression. Researchers want to find the best dose and check if it works safely.

Shanghai
NCT06827431Not yet recruiting· Phase 3
Testing ammoxetine for depression

This trial tests an investigational medication called ammoxetine for people with moderate to severe depression. It aims to see if the drug can reduce depressive symptoms and is for those who haven't had success with certain other antidepressants.

Hear when a new Depression trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.